Articles

My father’s estate was awarded $50K in a class-action lawsuit. My brother, as executor, kept the money. What can we do?

“My brother retains the money awarded to my father to this day. My mom is still alive.”

Here’s how Pinterest’s holiday quarter just became a worry for Wall Street

Pinterest’s stock drops about 20% on weaker revenue forecast for the shopping-heavy holiday quarter, usually the social-media company’s strongest.

Cava trims sales outlook amid heavy competition. But it’s wary of diving into the discounting fray.

Mediterranean fast-casual chain Cava Group reported third-quarter results that missed Wall Street’s estimates, as younger and middle-income consumers struggle with higher costs and competition remains stiff.

My girlfriend, a widow in her 40s, pays off her credit card after every transaction. Is that weird?

“I saw her transfer $150 after we were done shopping.”

Rivian rides expiring EV credits to a revenue beat, and its stock moves higher

The electric-vehicle maker expects its third-quarter delivery performance to be its best of the year.

Stadiums, shows abroad keep Live Nation upbeat on next year after sales miss expectations

Live Nation Entertainment said concert demand is set to stay strong into next year, helped by shows abroad and concerts at its biggest venues. However, the Ticketmaster parent company’s third-quarter sales came up short of Wall Street’s expectations.

Why Super Micro’s stock is falling after earnings — even as guidance moves higher

Super Micro continued to exhibit margin pressure in the latest quarter, reflecting a competitive server market.

Upstart’s stock extends declines as the AI lender predicts slower growth

Upstart’s December-quarter revenue is expected to slow more than Wall Street had been modeling.

Obesity drugs may be sold at just $149 a month, get covered under Medicare under a reported White House deal in the works

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries, according to media reports Tuesday.

AI has real problems. The smart money is investing in the companies solving them now.

This overlooked area of tech is making money for investors.

Palantir’s stock falls despite AI fueling another flurry of records

The software company is boosting its outlook, and its CEO is cheering gains for retail investors.

Amazon’s new OpenAI deal offers further proof the stock has become an AI winner

Last week Amazon CEO Andy Jassy hinted at more big deals. The $38 billion OpenAI partnership proves he wasn’t kidding.
1 240 241 242 243 244 2,560